Alyssa Felver
Primary Care · Lee, MANPI 1336765437
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$697
- AstraZeneca$594
- Johnson & Johnson$484
- Lundbeck LLC$467
- Pfizer$434
- Amgen$336
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,18298%
- Education$1072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 29 | $697 |
| AstraZeneca(2 entities) | 24 | $594 |
| Johnson & Johnson | 16 | $484 |
| Lundbeck LLC | 28 | $467 |
| Pfizer | 29 | $434 |
| Amgen | 14 | $336 |
| GSK | 17 | $297 |
| Otsuka America Pharmaceutical, Inc. | 16 | $296 |
| Novo Nordisk | 14 | $290 |
| Merck | 14 | $243 |
| Sumitomo Pharma America, Inc. | 9 | $235 |
| AbbVie | 10 | $232 |
| Astellas Pharma US Inc | 8 | $195 |
| Boehringer Ingelheim | 7 | $150 |
| Novartis | 7 | $139 |
| Exact Sciences | 5 | $112 |
| Abiomed | 1 | $104 |
| Sunovion Pharmaceuticals Inc. | 4 | $100 |
| Calliditas Therapeutics US Inc. | 1 | $99 |
| Sanofi | 1 | $90 |
| Impulse Dynamics (USA) Inc. | 1 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $77 |
| Indivior Inc. | 4 | $75 |
| Avanir Pharmaceuticals, Inc. | 2 | $48 |
| Amarin Pharma, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| UCB, Inc. | 1 | $30 |
| Corium, LLC | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Halozyme Inc | 1 | $18 |
| Biogen | 1 | $17 |
| Alkermes, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,289 in reported general payments places this provider in the 95th percentile of 181 primary care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $39,732 |
| OzempicSemaglutide | 32 | $31,927 |
| MyrbetriqMirabegron | 26 | $11,548 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,142 |
| Dexlansoprazole DrDexlansoprazole | 18 | $4,630 |
| Rosuvastatin Calcium | 89 | $4,556 |
| SlyndDrospirenone | 12 | $2,223 |
| Atorvastatin Calcium | 140 | $2,037 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,926 |
| Metoprolol Succinate | 80 | $1,625 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,477 |
| PaxlovidNirmatrelvir/Ritonavir | 23 | $1,429 |
| Levothyroxine Sodium | 126 | $1,096 |
| Losartan Potassium | 91 | $986 |
| Gabapentin | 63 | $857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $434 | $41,16157 claims |
| Novo NordiskOzempic | $290 | $31,92732 claims |
| Astellas Pharma US IncMyrbetriq | $195 | $11,54826 claims |
| AstraZenecaBreztri Aerosphere | $594 | $8,14213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 181 primary care providers in Massachusetts.
Other primary care in Lee
- Rebecca CaoLee$2K
- Christine HatchNewburyport$11K
- Kate McCabeWinchester$11K
- Katherine WatermanSpringfield$6K
- Joshua AbrahamsFoxborough$6K
- Glynelle WhiteFall River$6K
- Suhaiti VillaLawrence$5K
- Dmitry PrizandBoston$5K
- Ashley KoHaverhill$4K
- Melissa BorgesDartmouth$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.